Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 29;42(8):112881.
doi: 10.1016/j.celrep.2023.112881. Epub 2023 Jul 30.

Interplay between CXCR4 and CCR2 regulates bone marrow exit of dendritic cell progenitors

Affiliations
Free article

Interplay between CXCR4 and CCR2 regulates bone marrow exit of dendritic cell progenitors

Mariana Pereira da Costa et al. Cell Rep. .
Free article

Abstract

Conventional dendritic cells (cDCs) are found in most tissues and play a key role in initiation of immunity. cDCs require constant replenishment from progenitors called pre-cDCs that develop in the bone marrow (BM) and enter the blood circulation to seed all tissues. This process can be markedly accelerated in response to inflammation (emergency cDCpoiesis). Here, we identify two populations of BM pre-cDC marked by differential expression of CXCR4. We show that CXCR4lo cells constitute the migratory pool of BM pre-cDCs, which exits the BM and can be rapidly mobilized during challenge. We further show that exit of CXCR4lo pre-cDCs from BM at steady state is partially dependent on CCR2 and that CCR2 upregulation in response to type I IFN receptor signaling markedly increases efflux during infection with influenza A virus. Our results highlight a fine balance between retention and efflux chemokine cues that regulates steady-state and emergency cDCpoiesis.

Keywords: CP: Developmental biology; CP: Immunology; dendritic cells; emergency cDCpoiesis; immunology; influenza A virus infection; type I interferons.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests C.R.S. is a founder of Adendra Therapeutics and owns stock options and/or is a paid consultant for Adendra Therapeutics, Bicara Therapeutics, Montis Biosciences, and Bicycle Therapeutics, all unrelated to this work. C.R.S. also has an additional appointment as a visiting professor in the Faculty of Medicine at Imperial College London and holds honorary professorships at University College London and King’s College London.

References

Publication types

LinkOut - more resources